Login to Your Account

Evotec Finds New Partner for NMDA Drugs in Janssen Deal

By Nuala Moran
Staff Writer

Tuesday, December 18, 2012
A year and a half after Roche AG handed back rights, Evotec AG has found a new home for its NMDA antagonist portfolio, in a licensing deal with Janssen Pharmaceuticals Inc. worth a potential $75 million up to launch. In addition, there will be milestones payable on further products and/or indications, plus $100 million in commercial milestones on any products that get to market.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription